Trial Profile
Randomized, Prospective, Active-comparator Controlled, Patient-blinded Study to Demonstrate Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis Patients in Low Disease Activity and Remission - the REDOREM Study
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms REDOREM
- 16 Nov 2021 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT05116228).
- 02 Nov 2021 Status changed to discontinued due to failure to recruit.
- 12 Mar 2018 Status changed from active, no longer recruiting to completed.